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intervention (Fex-Can) targeting sexual
dysfunction and fertility-related distress in
young adults with cancer: study protocol of
a randomized controlled trial
C. Lampic1, L. Ljungman1, C. Micaux Obol1, L. E. Eriksson2,3,4 and L. Wettergren1*Abstract
Background: This study protocol describes the clinical trial of the Fex-Can intervention, a web-based self-help
program targeting sexual dysfunction and fertility-related distress. The psycho-educational intervention has been
developed in collaboration with young patients with cancer and shown to be feasible. The primary objective is to
determine whether the Fex-Can intervention, provided in addition to standard care, is superior to standard care in
terms of reduction of sexual dysfunction and fertility-related distress directly after end of the 12-week program. The
trial also aims to determine whether the intervention has an effect on the secondary outcomes including health-
related quality of life, anxiety, depression, body image, fertility knowledge, and self-efficacy related to sexuality and
fertility.
Methods: The trial has an randomized clinical trial (RCT) design with two parallel arms. The active groups receive
either the version of the Fex-Can intervention targeting sexual problems or the version targeting fertility-related
distress. Control groups receive standard care. Primary outcomes will be sexual function assessed with the Patient-
Reported Outcomes Measurement Information System® Sexual Function and Satisfaction measure version 2.0
(SexFS) and fertility-related distress assessed with the Reproductive Concerns After Cancer scale (RCAC). The effect
of the intervention will be evaluated directly after end of the program. Primary and secondary outcomes will also
be assessed at the short- (12 weeks after end of program) and long-term (20 and 44 months after end of program)
follow-up. At least 64 completers will be needed in each arm (total n = 256) to achieve adequate statistical power in
the analyses. In order to increase the understanding of how the intervention brings about a possible change, semi-
structured interviews will additionally be conducted with a purposeful sample shortly after completion of the
intervention.
Discussion: If the Fex-Can intervention proves to be efficacious the necessary steps will be taken to implement it
in routine care for young adults diagnosed with cancer. Healthcare could thereby be provided with an easily
accessible, cost-effective intervention to offer to young adults suffering from fertility-related distress or sexual
problems.
Trial registration: ISRCTN36621459. Registered 25 January 2016.© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background and rationale
Sexual dysfunction and fertility-related distress among
young adults are common in the aftermath of cancer.
Previous research has shown that about 50% in this
population report sexual dysfunction one year after the
cancer diagnosis [1]. Reduced sexual desire, dyspareunia,
vaginal dryness and low satisfaction with sex life are
commonly reported by women [2, 3], whereas erectile
dysfunction [4], orgasmic difficulties [5] and reduced
sexual interest [6] are reported by men. Several of the
most common cancer treatments (radiation therapy,
chemotherapy, endocrine treatment) may cause these
problems directly or indirectly via physiological, psycho-
logical, and interpersonal factors [7]. These treatments
may also cause temporary or permanent infertility or
subfertility [8]. A majority of young women with cancer
report fertility-related distress at clinical levels, which
also is related to reduced quality of life and to long-term
depressive symptoms [9]. Men’s experiences of fertility-
related distress after cancer have been studied to a lesser
extent and more research is needed to establish the
prevalence of clinical levels of distress by cancer type.
Importantly, young people with cancer have themselves
ranked both sexual problems and fertility concerns as
among their core needs that are unmet by the healthcare
today [10–12].
e-Health interventions have the potential to improve
quality of life and other behavioral outcomes by sup-
porting participants’ autonomy, competence, and re-
latedness [13]. While psychosocial interventions are
increasingly being used in young adults with cancer
[14], web-based interventions to overcome sexual and
reproductive problems are mostly lacking. One pro-
gram providing information about reproductive health
and fertility following cancer has shown positive ef-
fects in terms of social and physical functioning, and
improved fertility knowledge [15]. Also, a web-based
intervention to alleviate sexual problems among
women with cancer showed positive results over time,
but the participants were all 35 or older [16]. These
results indicate that e-health interventions have the
potential to contribute to improved sexual and repro-
ductive health in cancer populations, but that specific
attention should be given to the preferences and
needs of young people with cancer.
In order to address the problems mentioned above, we
initiated the project Fertility and Sexuality following
Cancer (Fex-Can). Within this project a web-based
intervention has been developed to fill the gap of
evidence-based psychosocial interventions to cope with
sexual dysfunction and fertility-related distress in young
people diagnosed with cancer. The Fex-Can intervention
has been developed in close collaboration with youngpatients with cancer and significant others [17]. If the
intervention proves to be efficacious, it can contribute to
improved sexual and reproductive health in young adults
with cancer.
The Fex-Can project, besides the development and
evaluation of the Fex-Can intervention, includes a
population-based cohort study (Fex-Can Cohort) moni-
toring sexual dysfunction and fertility-related distress in
young adults with cancer over 5 years following diagno-
sis. The Fex-Can intervention is evaluated in a random-
ized controlled trial (RCT) embedded in the Fex-Can
Cohort. The current protocol describes the RCT of the
Fex-Can intervention.
Objectives
The primary objective of the current trial is to determine
whether the Fex-Can intervention, provided in addition
to standard care, is superior to standard care in terms of
reduction of sexual dysfunction and fertility-related dis-
tress directly after end of the program. The trial also
aims to determine whether the intervention has an effect
on the secondary outcomes including health-related
quality of life, anxiety, depression, body image, fertility
knowledge, and self-efficacy related to sexuality and
fertility.
Trial design
The trial will have a two parallel-group pre-post and
follow-up (short- and long-term) superiority randomized
controlled design with a 1:1 allocation ratio. The active
groups will receive the Fex-Can Sexuality program
(Fex-Can Sex) or the Fex-Can Fertility program (Fex--
Can Fertility) according to level of self-reported prob-
lems. The intervention, Fex-Can Sex or Fex-Can
Fertility, will be compared with active control groups
who receive standard care, as shown in the Consolidated
Standards of Reporting Trials (CONSORT) flow diagram
(Fig. 1). This study protocol adheres to the SPIRIT state-
ment for clinical trial protocols [18, 19] and the
SPIRIT-PRO Extension [20].
Methods
Study setting
The sample for the Fex-Can RCT will be drawn from
participants at the baseline assessment of the Fex-Can
Cohort, which is described in detail in a separate
protocol. The Fex-Can Cohort investigates sexual dys-
function and fertility-related distress in persons diag-
nosed with selected cancers at the age of 18–39 over
a period of 5 years following diagnosis. The diagnoses
included in the Fex-Can Cohort are selected on the
basis that the diseases and/or their treatments may
have negative consequences for fertile ability and sex-
ual life. Participants in the Fex-Can Cohort are
Fig. 1 CONSORT standard RCT flow diagram (numbers, where they appear, are estimates at this stage)
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for Brain Tumors, Breast Cancer, Gynecological On-
cology, Lymphoma, and Testicular Cancer. Approxi-
mately 1500 individuals will be approached for the
Fex-Can Cohort and we estimate that about 1050
(70%) individuals will participate in the baseline as-
sessment by completing a survey (web or paper) ap-
proximately 1.5 year after diagnosis.Eligibility criteria
The following inclusion criteria will be used for the
Fex-Can RCT:1. Diagnosed with malignant brain tumor, breast
cancer, cervical cancer, lymphoma, ovarian cancer,
or testicular cancer when aged 18–39 years
approximately 1.5 years previously and subsequently
included in the Fex-Can Cohort.
2. Reporting sexual dysfunction or a high level of
fertility-related distress at the baseline assessment of
the Fex-Can Cohort. To be eligible for the Fex-Can
Sex program, individuals should report sexual
dysfunction (defined as 0.5 SD from the population
mean) in at least one of the selected domains of the
Patient-Reported Outcomes Measurement
Information System® Sexual Function and
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[21]. To be eligible for the Fex-Can Fertility
program, individuals should report a high level of
fertility distress (defined as a mean score > 3) in at
least one dimension of the RCAC (for further
specification of assessments, se primary outcomes
section below) [22]. In the event that individuals
meet the eligibility criteria for both programs, their
individual scores will be evaluated with regard to
severity of reported problems by a registered
psychologist and a registered nurse specialized in
psychosocial oncology. Based on a joint decision
these individuals will be allocated to one of the
programs accordingly.
The following exclusion criteria will be used for the
Fex-Can RCT:
1. Non-ability to read and/or understand Swedish
language.
2. Reporting poor health and/or significant cognitive
impairment that hinder participation in the
intervention.Intervention
The Fex-Can intervention consists of two programs,
The Fex-Can Sex and the Fex-Can Fertility, targeting
sexual dysfunction and fertility-related distress re-
spectively. The web-based self-help program has been
developed in accordance with theory [23] and through
a co-creative long-term collaborative process with pa-
tient research partners described in a previous publi-
cation [17]. The feasibility of the intervention has
been assessed with satisfying results indicating it to
be suitable for young persons with cancer regarding
demand, acceptability, preliminary efficacy, and func-
tionality [24].
Both programs, the Fex-Can Sex and the Fex-Can Fer-
tility, are organized in six consecutive modules which
will be delivered over a period of 12 weeks. The content
of the modules has been described in more detail in the
previous publication by Wiklander et al., [24]. The mod-
ules include information with educational and behavior
change content, exercises, illustrations, quizzes, and
video vignettes with young adults with cancer describing
their experiences regarding the topics addressed. The ex-
ercises aim at increasing sexual pleasure and functioning
(Fex-Can Sex) and handling threatened or lost fertility
(Fex-Can Fertility). The intervention also includes an
online-moderated joint discussion forum. In addition,
the sexuality program offers voluntary telephone consul-
tations at the beginning and end of the program aiming
to orientate the participant in terms of how the programcan be used and tailored to their specific needs. The
intervention is delivered via a platform created with a re-
sponsive design which can be used on computers, tab-
lets, and smartphones.
Adherence
To enhance participants’ adherence to the intervention
notifications by text message and/or e-mail will be sent
at the opening of each of the six modules.
Adherence will mainly be evaluated by the log func-
tion in the web platform, recording all information
about participants’ log-ins and use of different program
functions. Furthermore, the post-intervention assess-
ment (directly after end of program) will include ques-
tions about the participants’ use of different program
features in terms of frequency and intensity.
Concomitant care
Concomitant care and treatments for sexual dysfunction
and/or fertility-related distress will not be prohibited by
study participation.
Measurements
The standardized measures included in the study will be
used and analyzed in accordance with their respective
manual. The package of questionnaires has been tested
in two groups of young women and men with cancer
and showed to be well accepted [3]. See Table 1 for ad-
ministration of instruments.
Primary outcomes
Sexual function
The SexFS (version 2) is a set of measures developed to
assess sexual function and satisfaction in both men and
women, regardless of sexual orientation and if currently
being sexually active with partner/s or not. The primary
outcome for the Fex-Can Sex program is the score (con-
tinuous measure) in the domain ‘Satisfaction with sex
life’. This domain assesses how satisfying and pleasurable
current sexual activities are perceived; two selected items
will be used that are scored on a five-point scale (ran-
ging from 1 =None/Not at all to 5 = Very/A lot). Item
response theory is used to calculate the domain score
which is transformed to a T-score metric where 50 rep-
resents the mean for the American general population
(standard deviation = 10) [21]. Sexual dysfunction is de-
fined as 0.5 SD (5 points on the T-scale) from the popu-
lation mean of 50 in the respective domain. The SexFS
has shown adequate content, construct and known-
groups validity as well as test-retest reliability [21, 25].
The selected items and domains of the SexFS have been
translated into Swedish and linguistically validated in ac-
cordance with the procedure developed by FACITrans
and PROMIS [26].
Table 1 Timeline for Fex-Can RCT
Baseline (1.5 years
after diagnosis)
Post-intervention assessment
(directly after end of program)
Short-term follow-up
(12 weeks after end of
program)
Long-term follow-up
(20 months after end
of program)
Long-term follow-up
(44 months after end
of program)
Survey data
SexFS X Xa Xa X X
RCAC X Xb Xb X X
HADS X X X X X
EORTC QLQ-30 X X X X X
BIS X X X X X
Self-efficacy Sex X Xa Xa X x
Self-efficacy Fert X Xb Xb X X
Fertility related
knowledge
X Xb Xb X X
Clinical data
Diagnosis, type
and stage
X
Cancer treatment X
Semi-structured interview X
aPROMIS SexFS and Self-efficacy Sex is completed by participants in the Fex-Can Sexuality program; bThe RCAC, Self-efficacy Fert and Fertility related knowledge is
completed by participants in the Fex-Can Fertility program. Base-line assessment is collected at approximately one year after diagnosis and follow-up assessment
is based on time after end of program
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The primary outcome of the Fex-Can Fertility will be
the summary score of the Reproductive Concerns After
Cancer (RCAC). The RCAC is a multidimensional scale,
assessing a range of fertility and parenthood con-
cerns, developed and evaluated for young adult fe-
male cancer survivors (age 18–35 years) [22]. The
scale encompasses 18 items scored on a five-point
scale (ranging from 1 = Strongly disagree to 5 =
Strongly agree) and includes six dimensions. The di-
mensions (consisting of three items each) of the
RCAC are: Fertility potential, Partner disclosure,
Child’s health, Personal health, Acceptance and Be-
coming pregnant. In each dimension, high level of
reproductive concerns is defined as a mean score > 3.
The RCAC has demonstrated satisfactory internal
consistency and construct validity [9]. The scale has
independently been translated into Swedish by two
bilingual researchers, and has been evaluated by one
bilingual panel (n = 4), one lay panel (n = 7) and one
patient panel (n = 8), as well as by cognitive inter-
views with 3 young patients with cancer before the
launch of the Fex-Can project.Secondary outcomes
The secondary outcomes include additional domains
of sexual function (for participants in the Fex-Can
Sex) and fertility-related knowledge (for participantsin the Fex-Can Fertility). In addition, body image,
health-related quality of life, anxiety and depression,
self-efficacy (related to sexuality or fertility) measures
will be used as secondary outcomes in both arms.Sexual function
The following domains in the SexFS version 2 will be
used as secondary outcomes: Interest in sexual activ-
ity (2 items), Bother regarding sexual function (4
items), Orgasm-ability (1 item), Orgasm-pleasure (1
item), Vaginal lubrication (women, 2 items), Vaginal
discomfort (women, 4 items), Vulvar discomfort –
Labia (women, 1 item), Vulvar discomfort – Clitoral
(women, 1 item), and Erectile Function (men, 3
items). Domain scores are transformed to a T-score
metric where 50 represents the mean for the Ameri-
can general population (standard deviation = 10) [21].
Additionally, sexual activity screeners from the SexFS
will be used.Body image
Body image will be assessed using the Body Image
Scale (BIS) that measures body image discomfort as-
sociated with cancer and cancer treatment [27]. The
BIS encompasses 10 items and has shown high
test-retest reliability and good internal consistency in
cancer patients [27].
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Health-related quality of life will be measured using the
EORTC QLQ-C30 (version 3.0), which is a 30-item
questionnaire developed to assess the quality of life of
cancer patients [28, 29]. The EORTC QLQ-30 (v 3.0) in-
cludes five functional scales, three symptom scales, a
global health status scale, and six single items and has
demonstrated good psychometric properties in cancer
populations [28, 30]. The summary score for the
QLQ-30 will be used according to the EORTC
QLQ-C30 Scoring Manual (3rd Edition) (2001) and Gei-
singer et al. [29].Anxiety and depression
Anxiety and depression will be assessed using the
Hospital Anxiety and Depression scale (HADS) [31].
The HADS consists of two 7-item subscales, one
measuring symptoms of anxiety and the other symp-
toms of depression. The internal consistency of the
subscales has been reported to be satisfactory and the
concurrent validity has been reported to be good to
very good [32].Self-efficacy
Self-efficacy will be assessed by a study-specific ques-
tionnaire measuring confidence in one’s own ability to
handle situations, thoughts and emotions related to
the threat of infertility (6 items) and sexuality (6
items). Examples of questions assessing self-efficacy
are “I feel confident that I can handle negative
thoughts and emotions in relation to my sex life”
(Fex-Can Sex) and “I feel confident that I can handle
negative thoughts and emotions related to my repro-
ductive ability” (Fex-Can Fertility). Mean sum scores
range from 6 to 24, with higher scores indicating
higher levels of self-efficacy related to sexuality and
fertility, respectively.Fertility-related knowledge
Fertility-related knowledge will be examined by a
study-specific questionnaire with 10 items measuring
perceived level of knowledge about general and
cancer-related fertility issues. Responses are given on
a four-point scale ranging from 1 = Disagree com-
pletely to 4 = Agree completely. Examples of items are:
“I have good knowledge regarding the menstrual cycle
and when a pregnancy can occur” and “I have good
knowledge regarding the effect of cancer and cancer
treatments on reproductive ability”. The ratings on
the 10 items are summated giving sum scores with a
possible range from 10 to 40, with higher scores indicating
higher levels of perceived fertility-related knowledge.Administration of instruments
The instruments will be administered in the following
order at all assessments: BIS; RCAC; Self-efficacy Fertil-
ity; Fertility-related knowledge; Self-efficacy Sexuality;
SexFS; HADS; and EORTC QLQ-30. See Table 1 for out-
line of the study timeline.
Clinical data
Following formal consent from each registry, clinical
data will be collected from the National Quality Regis-
tries for Brain Tumors, Breast Cancer, Gynecological
Oncology, Lymphoma, and Testicular Cancer and include
cancer type and clinical stage, date of diagnosis, and type
of treatment. Clinical variables are selected in close collab-
oration with representatives from each of the respective
National Quality Registry, these are the same registers that
also were used for identification of potential participants
for the Fex-Can Cohort.
Process evaluation
Post-intervention survey
As part of the post-intervention assessment, participants
in the intervention groups (Fex-Can Sex and Fex-Can
Fertility) will be requested to respond to 13
study-specific items concerning their adherence, i.e. use
of the different features of the intervention (e.g. texts,
exercises and videos). They will also be asked to state
their opinions about the content and features of the
intervention. Responses are given on a four-point scale
ranging from “Disagree completely” to “Agree com-
pletely”. In addition, participants will be requested to de-
clare their current level of problems (regarding sex-life
or fertility-related distress) in comparison with their
level of problems before they entered the Fex-Can inter-
vention. Responses are given on a 7-point scale, ranging
from “Much improved” to “Much worsened” with the
midpoint “No change”.
Semi-structured interview
In order to increase the understanding of how the inter-
vention is used by participants and how it brings about a
possible change in the outcomes, semi-structured inter-
views will be conducted with a purposive sample of ap-
proximately 30 participants shortly after completion of
the intervention. During these interviews, which will be
conducted via telephone and transcribed verbatim, par-
ticipants’ views of their sexual dysfunction or fertility-
related distress and if/how these problems have changed
during the course of the intervention will be explored.
Participants will also be asked to describe their experi-
ences of participating in the intervention and their use
of the different program functions. Transcripts of the in-
terviews will be analyzed using [qualitative] content ana-
lysis [33].
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The Fex-Can project includes a large population-based
cohort study with an embedded RCT. This means that
participants in the Fex-Can RCT will be identified
among participants of the Fex-Can Cohort, based on
their self-report of sexual function and fertility distress
at the base-line assessment. Following randomization of
those who accept participation in the RCT, the interven-
tion groups (IG) receive access to the web-based inter-
vention delivered over 12 weeks and the control groups
(CG) receive standard care. All participants (IG and CG)
will be requested to complete two assessments (on
paper); directly after and 12 weeks after end of program.
The long-term follow-up assessments (20 and 44months
after end of program) will be conducted as part of the
data collection for the Fex-Can Cohort, and will be com-
pleted on paper or via the web. Primary and secondary
outcomes of the Fex-Can RCT are measured
pre-treatment (baseline assessment of the Fex-Can Co-
hort), at post-intervention assessment, and at the short-
and long-term follow-up assessments. See Table 1 for
study timeline.
Sample size
To detect a statistically significant difference with a
power of 80%, estimating medium effect size (0.5) and
α = 0.05, a total of 128 completers (post-intervention
assessment) will be needed in the Fert-Can Sex and
Fex-Can Fertility, respectively. We expect approxi-
mately 80% (n = 840) of the estimated 1050 partici-
pants in the Fex-Can Cohort to rate sexual dysfunction
and/or a high level of fertility distress. Of these we ex-
pect approximately 50% (n = 420) to agree to participa-
tion in the RCT, i.e. 210 participants in the Fex-Can
Sex and the Fex-Can Fertility, respectively. We esti-
mate an attrition of 15% at the post-intervention as-
sessment (directly after end of program) and another
15% at the short-term follow-up (12 weeks after end of
program), leaving 151 participants in the Fex-Can Sex
and Fex-Can Fertility, respectively. We therefore esti-
mate that the planned number of approached individ-
uals will be sufficient to achieve adequate statistical
power.
Recruitment
Individuals matching the inclusion criteria for the
Fex-Can RCT will be sent an information letter out-
lining the study procedures and the voluntary nature
of participation. Based on the self-reported problems
at the baseline assessment of the Fex-Can Cohort, po-
tential participants will be invited to participate in the
RCT, for either the Fex-Can Sex or the Fex-Can Fer-
tility. Acceptance of participation in the RCT is pro-
vided by return of a written informed consent form.Two reminders will be sent to non-responders. Based
on some difficulties recruiting participants to the
feasibility study of the Fex-Can [24] the information
letter states that participants will receive two cinema
tickets (total value of approximately 20 Euro) as in-
centives for completion of each assessment. No incen-
tive will be offered for participation in the post-
intervention semi-structured interview.
Randomization
Participants will be randomly assigned to either inter-
vention or control group with an allocation ratio of 1:1,
allocating participants in blocks stratified by sex and
diagnosis. This process will be performed separately for
the arms of the RCT (Fex-Can Sex and Fex-Can Fertil-
ity). A computer-generated randomization sequence
will be created by a statistician with no clinical involve-
ment in the trial. The details of the series of random
numbers is unknown to the investigators. Following
randomization, participants in the intervention groups
will receive a text message and/or e-mail with log-in
details to the program; individuals in the control groups
will be informed about their group allocation via mail
or e-mail.
Blinding (masking)
Due to the nature of the intervention, blinding of partic-
ipants to researchers involved in providing and monitor-
ing the intervention and data collection is not possible.
However, participants’ allocation to intervention or con-
trol groups will be masked in the data set available for
researchers during data analysis.
Statistical methods
Besides descriptive statistics and visualizations, the
main class of statistical method used will be linear
mixed models for longitudinal data. The statistical
analyses will primarily focus on comparing the
Fex-Can intervention with standard care between
baseline and directly after end of program. Missing
data will be analyzed using descriptive statistics and
significance testing. Intention-to-treat will be applied
for analyses of the primary outcomes. Statistical ana-
lyses will be performed in collaboration with exter-
nal statisticians, who are not informed about the
study participants’ group allocation. SPSS Statistics
version 25 (IBM Corp., Armonk, N.Y., USA) will be
the primary tool for data management and statistical
analyses.
Adverse effects
Adverse effects will be evaluated by number of partici-
pants reporting possible worsening of symptoms in the
primary or secondary outcomes. Participants furthermore
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experienced worsening of symptoms of any kind. Add-
itionally, the semi-structured post-intervention interview
will include a question regarding possible adverse effects
experienced by the participants.
Ethics and dissemination
Research ethics approval
Ethical approval has been obtained for the study proce-
dures by the Regional Ethical Review Board in
Stockholm, Sweden (Dnr: 2013/1746–31/4; 2014/2244–
32; 2017/916–32; 2017/1416–32).
Confidentiality
All participants will receive a unique code number in-
dicated on the survey. The code key will be stored
separate from the research data and will only be ac-
cessible by members of the research team. Partici-
pants will log in to the web portal by using an alias
of their own choice. The researchers will be able to
connect participants’ alias to the code number at the
stage of analyzing data. All data will be handled and
stored according to the EU General Data Protection
Regulation (GDPR).
Dissemination policy
The results from the trial will be communicated to the
scientific, clinical and patient communities through pub-
lications in scientific peer-reviewed open-access journals
and presentations at international clinical and scientific
conferences and in other contexts.
Discussion
Numerous studies have reported sexual problems and
fertility-related distress to be common among young
adults following a cancer diagnosis [1, 9]. Young
adults with cancer have furthermore themselves
ranked both sexual problems and fertility concerns as
among their core problems in the aftermath of cancer
[10–12]. Still, evidence-based interventions treating
these problems are lacking. The Fex-Can intervention
is a web-based self-help program targeting sexual
problems and fertility-related distress in young adults
diagnosed with cancer. The Fex-Can intervention has
been developed in close cooperation with young
patients with cancer and significant others [19], and
has previously been evaluated as to its feasibility with re-
sults indicating it to be acceptable and safe to use [24].
The current study protocol describes the procedures for
the clinical trial of the Fex-Can intervention.
The design of the trial has several significant
strengths. First, a key strength is the RCT design which
is the “gold standard” in clinical research and allows
firm conclusions with regard to the efficacy of theintervention. Also, as the trial has a two parallel-arm
design, both versions of the intervention, the Fex-Can
Sex (targeting sexual problems) and the Fex-Can Fer-
tility (targeting fertility-related distress) will be evalu-
ated. Another significant strength of the design is the
use of both short- and long-term follow-up assess-
ments. In the previous literature, long-term evalua-
tions (> 2 years) of web-based interventions have rarely
been conducted [34]. The long follow-up period in this
project, 20 and 44 months after the intervention, will
thus enable conclusions with regard to a potential last-
ing effect of the intervention. Furthermore, the use of
national quality registers allows identification of the
total population of young adults diagnosed with the
cancer diagnoses selected for the project, as well as
provision of clinical data of high quality. The quality of
the survey data is also high due to the use of validated
instruments. Lastly, the use of secondary outcomes will
allow investigation of potential additional effects, as
well as of interactions with other important processes
related to the outcomes targeted by the intervention,
and will therefore increase the clinical relevance of
conclusions.
Some potential weaknesses of the trial should also
be mentioned. First, as prevalence rates for sexual
problems and fertility-related distress following dif-
ferent cancer diagnoses have not yet been established,
there are some uncertainties with regard to inclusion
and retention rate. This may impact on the time
needed to include a sufficient number of participants
to reach adequate statistical power. Also, the design
with no active treatment for the control-group aside from
standard care should be mentioned as it may imply a risk
of general, rather than specific, effects by the intervention.
Future studies should compare the effects of different in-
terventions on these issues. Lastly, the cut-off values used
for inclusion have not been evaluated previously, and the
relevance of sexual problems and fertility-related distress
at levels above the cut-offs used in this trial are yet to be
determined.
In conclusion, the current study protocol describes the
clinical trial of the Fex-Can intervention which is the first
web-based intervention targeting sexual problems and
fertility-related distress in young adults diagnosed with can-
cer. Should the Fex-Can intervention prove to be effica-
cious, in the short- and/or in the long-term, we will take
the necessary steps to implement it in routine care for
young adults diagnosed with cancer. Healthcare could
thereby be provided with an easily accessible, cost-effective
intervention to offer to young adults suffering from
fertility-related distress or sexual problems. This interven-
tion thus has the potential to advance health care, and to
improve the reproductive and sexual health in young
people diagnosed with cancer in the future.
Appendix
Table 2 Items from the World Health Organization Trial Registration Data Set
Data category Information
Primary registry and trial identifying number ISRCTN
ISRCTN36621459
Date of registration in primary registry 25 January 2016
Secondary identifying numbers https://doi.org/10.1186/ISRCTN36621459
Source(s) of monetary or material support Karolinska Institutet
Primary sponsor Cancer Research Foundations of Radiumhemmet
Swedish Cancer Society
Swedish Childhood Cancer Foundation
Vårdal Foundation
Swedish Research Council for Health, Working Life and Welfare
Swedish Research Council
Secondary sponsor(s) Doctoral School in Health Care Sciences at Karolinska Institutet
Contact for public queries Lena Wettergren, PhD [+46 (0)8524836 50] [lena.wettergren@ki.se]
Claudia Lampic, PhD [+ 46 (0)8524823 70] [claudia.lampic@ki.se]
Contact for scientific queries Lena Wettergren, PhD
Karolinska Institutet, Sweden
Public title Fex-Can – Fertility and sexuality following cancer
Scientific title Fex-Can – interventions to alleviate impact of cancer on fertility and sexuality among
adolescents and young adults
Countries of recruitment Sweden
Health condition(s) or problem(s) studied Brain tumor, breast cancer, cervical cancer, lymphoma, ovarian cancer, and testicular cancer
Intervention(s) The Fex-Can intervention consists of two programs, The Fex-Can Sex and the Fex-Can Fertility,
targeting sexual dysfunction and fertility-related distress respectively. They are web-based self-help
programs delivered over a period of 12 weeks.
Key inclusion and exclusion criteria Ages eligible for study: 18–39 years at diagnosis
Sexes eligible for study: both
Accepts healthy volunteers: no
Inclusion criteria: adult patient (≥ 18 years) approximately 18 months after being diagnosed with
cancer. Reporting sexual dysfunction or a high level of fertility-related distress.
Exclusion criteria: non-ability to read and/or understand Swedish language. Reporting poor health
and/or significant cognitive impairment that hinder participation in the intervention.
Study type Interventional
Allocation: randomized
Intervention model: parallel assignment in blocks stratified by sex and diagnosis. The process will be
performed separately for the arms of the RCT (Fex-Can Sex and Fex-Can Fertility)
Masking: not possible due to the nature of the intervention
Primary purpose: Efficacy trial
Date of first enrolment September 2017
Target sample size 256
Recruitment status Recruiting
Primary outcome(s) The primary outcome for the Fex-Can Sex program is the score (continuous measure) of the domain
‘Satisfaction with sex life’, a subscale of the Patient-Reported Outcomes Measurement Information
System® Sexual Function and Satisfaction measure. The primary outcome of the Fex-Can Fertility will
be the summary score of the Reproductive Concerns After Cancer (RCAC).
Key secondary outcomes Additional domains of sexual function (for participants in the Fex-Can Sex) and fertility-related
knowledge (for participants in the Fex-Can Fertility). In addition, body image, health-related quality
of life, anxiety and depression, self-efficacy (related to sexuality or fertility) measures will be used as
secondary outcomes in both arms.
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BIS: Body image scale; Fex-Can Cohort: Fex-Can population-based cohort
study; Fex-Can Fertility: Fex-Can fertility intervention; Fex-Can Sex: Fex-Can
sexuality intervention; Fex-Can: Fertility and sexuality following cancer;
GDPR: General data protection regulation; HADS: Hospital anxiety and
depression scale; PROMIS: Patient-Reported Outcomes Measurement
Information System®; RCAC: Reproductive concerns after cancer scale;
RCT: Randomized controlled trial; SexFS: Sexual function and satisfaction
measure
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